Ustekinumab: "Real-world" outcomes and potential predictors of nonresponse in treatment-refractory Crohn's disease.

CONCLUSION: In a "real-world" treatment-refractory cohort of patients with CD, ustekinumab appeared efficacious and safe.
PMID: 31496626 [PubMed - in process]

Source: World Journal of Gastroenterology : WJG - August 20, 2019 Category: Gastroenterology Authors: Hoffmann P, Krisam J, Wehling C, Kloeters-Plachky P, Leopold Y, Belling N, Gauss A Tags: World J Gastroenterol Source Type: research